Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis

Elisabetta Cocconcelli1 · Roberto Tonelli2,3 · Gianluca Abbatì4 · Alessandro Marchioni2 · Ivana Castaniere2,3 · Filippo Pelizzaro2 · Francesco Paolo Russo2 · Alberto Vegetti4 · Elisabetta Balestro1 · Antonello Pietrangelo4 · Luca Richeldi6 · Fabrizio Luppi7 · Paolo Spagnolo1 · Enrico Clini2 · Stefania Cerri2

Received: 14 March 2020 / Accepted: 12 May 2020 / Published online: 25 May 2020
© Società Italiana di Medicina Interna (SIMI) 2020

Abstract
Data on the presence of subclinical fibrosis across multiple organs in patients with idiopathic lung fibrosis (IPF) are lacking. Our study aimed at investigating through hepatic transient elastography (HTE) the prevalence and clinical impact of subclinical liver fibrosis in a cohort of patients with IPF. Patients referred to the Centre for Rare Lung Disease of the University Hospital of Modena (Italy) from March 2012 to February 2013 with established diagnosis of IPF and without a documented history of liver diseases were consecutively enrolled and underwent HTE. Based on hepatic stiffness status as assessed through METAVIR score patients were categorized as “with liver fibrosis” (corresponding to a METAVIR score of F1–F4) and “without liver fibrosis” (METAVIR F0). Potential predictors of liver fibrosis were investigated through logistic regression model among clinical and serological variables. The overall survival (OS) was assessed according to liver fibrosis and multivariate Cox regression analysis was used to identify independent predictors. In 13 out of 37 patients (35%) with IPF, a certain degree of liver fibrosis was documented. No correlation was found between liver stiffness and clinical–functional parameters. OS was lower in patients ‘with liver fibrosis’ than in patients ‘without liver fibrosis’ (median months 33 [23–55] vs. 63 [26–94], \(p = 0.038\)). Patients ‘with liver fibrosis’ presented a higher risk of death at seven years as compared to patients ‘without liver fibrosis’ (HR = 2.6, 95% CI [1.003–6.7], \(p = 0.049\)). Higher level of AST to platelet ratio index (APRI) was an independent predictor of survival (HR = 4.52 95% CI [1.3–15.6], \(p = 0.02\)). In our cohort, more than one-third of IPF patients had concomitant subclinical liver fibrosis that negatively affected OS. These preliminary claims further investigation aimed at clarifying the mechanisms beyond multiorgan fibrosis and its clinical implication in patients with IPF.

Keywords Lung fibrosis · Liver fibrosis · Hepatic transient elastography

Abbreviations

BMI  Body mass index
TLC  Total lung capacity
FVC  Forced vital capacity
DLCO  Diffuse lung capacity for carbon dioxide
GAP  Sex, age, pulmonary function (FVC, DLCO)
PBC  Primary biliary cirrhosis
PSC  Primary sclerosing cholangitis
AMA  Antimitochondrial antibody
ASMA  Anti-smooth muscle antibodies
AST  Aspartate aminotransferase
ALT  Alanine aminotransferase
γGT  Gamma-glutamyl transferase
IgG4  Immunoglobulin G4
APRI  AST to platelet ratio index
PH  Pulmonary hypertension

Background

Fibrogenesis is a key mechanism of tissue repair representing a physiological response to injury [1]. In some pathological conditions, however, this pathway may be dysregulated so that undue fibroproliferation and extracellular matrix deposition occur, leading to tissue injury and dysfunction [2]. Every tissue or organ may potentially be involved. While tissue-specific injury has different origin, responses to injury and repair mechanisms are similar across different organs [3]. Many distinct causes can contribute to the development of progressive fibrotic diseases, including
genetic abnormalities, infections, exposure to toxins or pollutants, micro-aspiration of gastric content, tobacco smoke, and chronic autoimmune inflammation [4].

In idiopathic pulmonary fibrosis (IPF), a specific form of chronic and progressive interstitial pneumonia, repeated subclinical damages to alveolar epithelial cells (AECs) superimposed on accelerated epithelial aging lead to abnormal healing processes and deposition of interstitial fibrosis by fibroblasts and myofibroblasts [5, 6]. IPF represents a particularly arduous challenge, as, in contrast to other forms of lung injury, knowledge about the inciting injury, progressive fibroproliferation, and lack of resolution are only partially understood [6–8]. Consequently, there are no therapies able to halt or reverse the fibrotic process of IPF.

Whether the activation of a fibrotic response in one organ might induce similar manifestations in other organs, as a result of the activation of common pathways, is unknown. Specifically, robust data about the co-existing presence of fibrotic disease across multiple organs in patients with IPF are lacking. With this background, the aim of our study is to evaluate the prevalence and clinical relevance of subclinical hepatic fibrosis through hepatic transient elastography (HTE) in patients diagnosed with IPF without clinically overt liver disease.

Materials and methods

Study population

We consecutively enrolled patients with established diagnosis of IPF referred to the Centre for Rare Lung Diseases of the University Hospital of Modena (Italy) over a 12-month period (from March 2012 to February 2013). Demographic, clinical and functional data (forced vital capacity [FVC], and diffusing capacity of the lung for carbon monoxide [DLCO]) were recorded at the time of diagnosis. Each patient started antifibrotic treatment (either pirfenidone or nintedanib) at diagnosis. Disease severity score of IPF patients was recorded using the GAP-staging system, which includes sex, age, FVC, and DLCO [9]. The occurrence of pulmonary hypertension (PH) defined as mean pulmonary artery pressure of ≥25 mmHg on right heart catheterization or estimated systolic pulmonary artery pressure of ≥40 mmHg on echocardiography was collected during the follow-up period [10].

The exclusion criteria were documented history of chronic liver disease of known cause, and positive screening for potential secondary causes of liver fibrosis including positive serology for chronic hepatitis B or C virus infection, history of alcohol abuse (>2 units of alcohol), pharmacological treatments with prevalent hepatic metabolism, body mass index (BMI) >29 kg/m², metabolic syndrome and inability to express a valid informed consent.

The study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the University Hospital of Modena (Prot n. 2645). Informed consent was obtained for all study participants.

Liver stiffness evaluation

HTE was performed using Fibroscan® (Echosense™, Paris, France) at the Hereditary and Metabolic Center for Liver Diseases of the University Hospital of Modena. The exam was performed by internal medicine physicians experienced in hepatic fibrosis who were blinded to the past medical history of each patient and to the design of the study. HTE was performed with patient lying flat on the back, with the right arm tucked behind the head to facilitate the access to the hepatic right lobe. The tip of the probe transducer was placed on the skin between the rib bones at the level of the right hepatic lobe. Once the measurement area had been located, signal acquisition was started. The Fibroscan® internal software (Echosense™, Paris, France) determined whether each measurement was successful or not. The overall liver stiffness corresponded to a mean of ten successful measurements and was expressed in kiloPascals (kPa). Liver stiffness values ranged from 2.5 to 75 kPa and were immediately available and operator independent [11]. Liver kPa stiffness threshold values were related to METAVIR parameters. In particular, value range 0–5.2 kPa corresponded to METAVIR F0 (absence of fibrosis), range 5.3–7.4 kPa to METAVIR F1 (fibrosis exists with expansion of portal zones—mild fibrosis), range 7.5–9 kPa to METAVIR F2 (fibrosis exists with expansion of most portal zones and occasional bridging—significant fibrosis), range 9.1–13.1 kPa to METAVIR F3 (fibrosis exists with expansion of most portal zones and marked bridging and occasional nodules—severe fibrosis), range 13.2–75 kPa to METAVIR F4 (cirrhosis) [12].

Based on METAVIR parameters, IPF patients were categorized as ‘with liver fibrosis’ (if METAVIR value correspond to F1, F2, F3, F4) or ‘without liver fibrosis’ (if METAVIR value correspond to F0). All patients enrolled in the study were further investigated for liver disease. These investigations included autoantibodies for the autoimmune hepatitis, primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) (anti-nuclear antibodies [ANA], anti-liver and kidney microsomes [anti-LKM] antibodies, antimitochondrial antibodies [AMA], anti-smooth muscle antibodies [ASMA]), serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (γGT), bilirubin, iron, and circulating immunoglobulins G4 (IgG4). The AST to platelet ratio index (APRI), a predictor of liver fibrosis, was
calculated as follows: AST/upper limit of normal × 100/platelet count [13, 14].

**Statistical analysis**

Categorical variables are expressed as absolute (n) and relative values (%) whereas continuous variables as median and interquartile range (IQR). To compare demographic data and baseline clinical characteristics between IPF patients ‘with liver fibrosis’ and IPF patients ‘without liver fibrosis’, Chi-square test and Fisher’s exact test for categorical variables and Mann–Whitney U test for continuous variables were used, as appropriate.

The correlation between liver stiffness values in kPa and each serum parameter was assessed for the entire study population and in the two groups of IPF patients (with liver fibrosis and without liver fibrosis) with the nonparametric Spearman’s rank method. Univariate logistic regression analysis was performed to detect the predictors of liver fibrosis, and variables significantly or borderline significantly (0.05 < p < 0.09) associated with liver fibrosis were inserted in a multivariate logistic regression model to determine the independent predictors.

The overall survival (OS) was calculated from the date of diagnosis to the date of death. Patients treated with lung transplantation and those lost to follow-up were censored at the time of transplantation or at the last follow-up visit. In patients alive at the end of the study, data were censored on September 1st, 2019. The cumulative survival rate was calculated using Kaplan–Meier method and the difference in the survival time between the two groups (‘with liver fibrosis’ and ‘without liver fibrosis’) was assessed with log-rank test. A multivariate Cox regression analysis was used to determine which clinical and serological features were independently associated with survival. Only variables with a statistically significant and almost significant (0.05 < p < 0.09) association with OS at the univariate analysis were included in the multivariate model.

All data were analyzed using SPSS Software version 25.0 (New York, NY, USA: IBM Corp. USA). p values < 0.05 were considered statistically significant. The statistical package GraphPad Prism 7.0 (GraphPad Software, Inc. La Jolla, CA, USA) was used for graphs.

**Results**

Forty-eight consecutive IPF patients were considered and 37 were finally enrolled in the study (Table 1). In 29 patients (78%), HTE measurements for liver stiffness were considered reliable while for 8 patients (22%), HTE measurements were unsuccessful as the software could not determine a final mean measurement of liver stiffness from ten valid measurements. Sixteen out of the 29 patients (55%) had a median liver stiffness value of 3.65 kPa (2.60—5.10 kPa) corresponding to a METAVIR value of F0 and were classified as ‘without liver fibrosis’. Four patients had a median liver stiffness of 6.70 kPa (6.10–7.40 kPa) corresponding to a METAVIR value of F1, six patients had a median liver stiffness of 7.70 kPa (7.60–8.40 kPa) corresponding to a METAVIR value of F2, one patient had a liver stiffness value of 9.50 kPa corresponding to a METAVIR value of F3, and two patients had a liver stiffness value of 14.30 and 45.30 kPa corresponding to a METAVIR value of F4.
index (BMI), glucose blood levels, radiological diagnosis) as well as functional parameters (FVC, DLCO, GAP score) (Table 2). 13/29 patients developed PH during the follow-up period, with similar occurrence between patient ‘with liver fibrosis’ and ‘without liver fibrosis’ (Table 2).

### Serum analysis and correlations

Blood tests (glucose, AST, ALT, γGT, platelets, total bilirubin, APRI, IgG4, iron, ferritin and transferrin) were similar in patients ‘with liver fibrosis’ and ‘without liver fibrosis’ (Table 2). Notably, one of the two patients with F4 on HTE measurements had also high IgG4 levels (i.e., 419 mg/dL; normal values defined as lower than 86 mg/dL) and underwent liver biopsy, which revealed chronic idiopathic liver disease. No correlation between liver stiffness values (kPa) and clinical–functional parameters (age, smoking history, BMI, FVC, DLCO, GAP score) or blood tests (AST, ALT, γGT, APRI, IgG4, ferritin and transferrin) was found, neither in the entire study population of IPF patients evaluated for liver fibrosis nor when it was stratified by the presence/absence of liver fibrosis. Sex, functional data at baseline, APRI test, and AST/ALT/γGT were not associated with liver fibrosis at univariate logistic regression (Table 3). Therefore, with any correlation being absent at univariate analysis, it was not possible to build a multivariate logistic regression model.

### Survival analysis

Survival was estimates during a follow-up time of 7 years, with median OS of 4 months. The OS of patients ‘with liver fibrosis’ was lower than patients ‘without liver fibrosis’, with a median OS of 33 (10–95) months for patient ‘with liver fibrosis’ and 63 (3–110) months for patients ‘without liver fibrosis’ ($p=0.038$) (Fig. 2). Patients with liver fibrosis presented higher risk of death at 7 years as compared to baseline.

---

### Table 2

Baseline characteristics of the 29 IPF patients evaluated for liver stiffness, of which 16 without liver fibrosis on HTE measurements and 13 with liver fibrosis

| Variable                  | Population evaluated for liver fibrosis ($n=29$) | Without liver fibrosis ($n=16$) | With liver fibrosis ($n=13$) | $p$     |
|---------------------------|-----------------------------------------------|---------------------------------|-----------------------------|---------|
| Male, $n$ (%)             | 21 (72)                                       | 10 (62)                         | 11 (85)                     | 0.23    |
| Female, $n$ (%)           | 8 (28)                                        | 6 (38)                          | 2 (15)                      |         |
| Age at diagnosis, years   | 71 (42–83)                                    | 75 (42–83)                      | 66 (54–78)                  | 0.04    |
| Smoking history, pack/years | 10 (0–64)                                    | 3 (0–64)                        | 21 (0–45)                   | 0.42    |
| BMI, kg/m²               | 23 (20–27)                                    | 24 (20–27)                      | 22 (20–26)                  | 0.15    |
| Glucose (mg/dL)          | 101 (81–146)                                  | 122 (87–146)                    | 90 (81–142)                 | 0.13    |
| Radiological diagnosis, $n$ (%) | 22 (76)                                      | 13 (81)                         | 9 (69)                      | 0.66    |
| Histological diagnosis, $n$ (%) | 7 (24)                                       | 3 (19)                          | 4 (31)                      |         |
| FVC at diagnosis, %pred   | 78 (22–120)                                   | 72 (22–120)                     | 79 (45–98)                  | 0.34    |
| DL$_{CO}$ at diagnosis, %pred | 35 (11–102)                                | 38 (11–65)                      | 35 (23–102)                 | 0.80    |
| GAP score                |                                               |                                 |                             |         |
| I                         | 11 (38)                                       | 5 (31)                          | 6 (46)                      | 0.62    |
| II                        | 14 (48)                                       | 9 (56)                          | 5 (39)                      |         |
| III                       | 4 (14)                                        | 2 (13)                          | 2 (15)                      |         |
| Liver stiffness, kPa      | 4.50 (2.60–45.30)                             | 3.65 (2.60–5.10)                | 7.60 (6.10–45.30)           | <0.0001 |
| APRI                      | 0.23 (0.16–1.24)                              | 0.25 (0.17–0.51)                | 0.23 (0.16–1.24)            | 0.78    |
| Platelets, $n\times 10^9$/L | 250 (156–363)                               | 251 (157–363)                   | 236 (156–324)               | 0.37    |
| AST, U/L                  | 20 (13–82)                                    | 20 (15–27)                      | 22 (13–82)                  | 0.86    |
| ALT, U/L                  | 15 (8–80)                                     | 14 (8–29)                       | 28 (8–80)                   | 0.10    |
| γGT, U/L                  | 21 (12–643)                                   | 20 (12–42)                      | 42 (12–643)                 | 0.14    |
| Bilirubin total, µmol/L   | 0.43 (0.24–1.45)                              | 0.40 (0.26–0.65)                | 0.51 (0.24–1.45)            | 0.23    |
| IgG4, mg/dL               | 52 (10–618)                                   | 52 (23–618)                     | 96 (10–433)                 | 0.88    |
| Iron, µmol/L              | 91 (19–175)                                   | 104 (86–139)                    | 78 (19–175)                 | 0.18    |
| Ferritin, µg/L            | 99 (22–276)                                   | 92 (22–276)                     | 135 (59–227)                | 0.93    |
| Transferrin, g/L          | 357 (258–522)                                 | 335 (258–399)                   | 379 (275–522)               | 0.48    |
| PH, $n$ (%)               | 13 (45)                                       | 7 (44)                          | 6 (46)                      | 0.99    |

Data are presented as number and percentage for dichotomous values or median and ranges for continuous values.
patients without liver fibrosis (HR 2.6, 95% CI 1.003–6.7; \( p = 0.049 \), Fig. 2) (Fig. 3).

Univariate analysis of factors associated with survival revealed that lower DLCO at diagnosis, GAP score III compared to GAP score I, presence of liver fibrosis, and high levels of APRI score had a significant negative association with survival in the whole IPF population (Table 4). Multivariate analysis showed that only high level of APRI was an independent predictor of survival in our IPF cohort (HR: 4.52 95% CI [1.3–15.6]; \( p = 0.02 \)).

**Discussion**

Our study aimed at non-invasively assessing whether IPF patients without a clinical overt liver disease may present subclinical hepatic fibrosis. We found that IPF patients presented a significant prevalence of liver fibrosis (35%) that negatively affected survival.

To our knowledge, robust evidences about the co-existing presence of fibrotic disease across multiple organs in patients with IPF are lacking. Collagen deposition is an indispensable and typically reversible part of wound healing, even though normal tissue repair can evolve into a progressive and irreversible fibrotic response when tissue injury is severe or if the wound-healing response is dysregulated [1, 2, 15]. A feature shared by all fibrotic diseases is the activation and differentiation of fibroblasts into myofibroblasts, which are specialized contractile cells with higher profibrotic potential than fibroblasts. Within the fibroblastic foci, which define the histological usual interstitial pneumonia (UIP) pattern of lung fibrosis observed in IPF, myofibroblasts cause exaggerated extracellular matrix (ECM) deposit, which is the hallmark of the scarring process [15].

**Table 3** Predictive factors of liver stiffness in the entire population of IPF patients evaluated for liver stiffness on Fibroscan® measurements

|                | OR (95% CI)     | \( p \) value |
|----------------|-----------------|---------------|
| Sex            |                 |               |
| Female         | Ref             |               |
| Male           | 3.30 (0.60–26.26) | 0.19          |
| Age at diagnosis |               |               |
| <60            | Ref             |               |
| >60            | 0.95 (0.86–1.02)  | 0.17          |
| FVC at diagnosis, % pred |     |               |
| >60            | Ref             |               |
| 60–80          | 0.14 (0.006–1.25) | 0.11          |
| <60            | 0.59 (0.10–3.08)  | 0.53          |
| DLCO at diagnosis, % pred |     |               |
| >50            | Ref             |               |
| 35–50          | 0.66 (0.067–5.53) | 0.70          |
| <35            | 0.33 (0.03–2.8)   | 0.31          |
| GAP score      |                 |               |
| I              | Ref             |               |
| II             | 1.2 (0.11 to 13.3) | 0.87          |
| III            | 0.55 (0.01–1.08)  | 0.60          |
| Platelets, \( n \times 10^9/L \) | |               |
|                 | 0.99 (0.98–1.01)   | 0.43          |
| APRI           | 4.98 (0.12—874.1)  | 0.42          |
| AST, U/L       | 1.05 (0.97–1.18)   | 0.29          |
| ALT, U/L       | 1.08 (1.01–1.19)   | 0.06          |
| γGT, U/L       | 0.04 (1.00–1.11)   | 0.10          |
| IgG4, mg/dL    | 1.00 (0.99–1.00)   | 0.63          |
| Iron, μmol/L   | 0.98 (0.95–1.00)   | 0.30          |
| Glucose, mg/dL | 0.96 (0.90–1.01)   | 0.16          |
| PH             |                 |               |
| No             | Ref             |               |
| Yes            | 1.10 (0.25–4.87)   | 0.89          |

Values are expressed as HR (95% CI). Logistic regression analysis in relation to liver stiffness was used to determine the relationship of clinical, functional and serum levels of liver function with liver stiffness development.
Pathological liver fibrosis is similarly characterized by excessive accumulation of ECM proteins, (fibrillar collagens, glycoproteins, and proteoglycans) and is induced by activated myofibroblasts [16]. Bridging fibrosis and regeneration nodes are the clearest manifestation of this injury, with cirrhosis being the end stage of this process [17]. Excessive collagen deposition distorts the normal liver tissue architecture, leading to hepatocellular dysfunction and increased hepatic resistance to blood flow, which cause hepatic insufficiency and portal hypertension [18, 19].

Our data show that more than one-third of IPF patients have a concomitant and clinically unremarkable fibrosing process in the liver. Having excluded subjects with potentially secondary causes for liver diseases, our IPF cohorts seem to be affected by an idiopathic/cryptogenic liver fibrosis. At baseline, IPF patients' with 'and 'without liver fibrosis can be compared in terms of demographic, clinical, functional, and serological characteristics. These comparisons can be performed using statistical methods such as univariate and multivariate Cox proportional hazard regression tests to determine the relationship of clinical, functional, and serological characteristics with survival.
fibrosis’ are homogeneous in terms of clinical and functional data as well as serological tests. Of interest, patients ‘with liver fibrosis’ gain the diagnosis of IPF younger as compared to patients ‘without liver fibrosis’, maybe because the systemic involvement leads to an earlier onset of symptoms and disease awareness. Two examples of potential common pathways responsible for fibrotic processes occurring in different organs were proposed in the past: (1) excessive telomere shortening, as a consequence of telomerase gene mutations, ultimately leading to apoptosis and organ failure, not only in the lung, but also in the liver; (2) germ-line mutations in telomerase components hTERT and hTR that are found in a subset (8–15%) of patients with familial pulmonary fibrosis [20, 21]. Moreover, as compared with age-matched controls, patients with IPF have shorter telomeres regardless of whether they carry telomerase-related mutations [22, 23]. In the liver, excessive telomere shortening, as a consequence of telomerase gene mutations may impair the hepatocyte regenerative ability in response to chronic damage, thus facilitating fibrosis progression.

Although percutaneous biopsy has traditionally been considered as the gold standard for the diagnosis and staging of chronic liver diseases, researchers have invested many efforts to develop noninvasive tests able to evaluate liver fibrosis. Both instrumental and serological methods to evaluate liver fibrosis were developed and validated [11, 24–29]. Among these, HTE has been evaluated as a non-invasive method for assessing liver fibrosis in a variety of chronic liver diseases while APRI is a simple index calculated with readily available laboratory results that proved to identify with a high degree of accuracy the presence of significant fibrosis and cirrhosis in patients with chronic HCV-related hepatitis [30]. The mean liver stiffness value discovered in healthy patients without overt causes of liver disease and normal liver enzymes has been estimated 5.5 ± 1.6 kPa [11, 31]. Age has no influence, but liver stiffness values have been found higher in obese patients and males [11]. Liver stiffness assessment can be difficult in patients with BMI> 29 and in those with narrow intercostal space and cannot be performed in patients with ascites. According to experienced reported measurements, liver stiffness cannot be measured in 5–15% of cases [25–28]. In our study, we have observed a greater proportion of unreliable measurements (22%) mainly due to either increased thickness of subcutaneous adipose tissue of the chest (n = 6) or narrow intercostal spaces (n = 2).

Of great interest, our data showed that patients ‘with liver fibrosis’ have a shorter survival as compared to patients ‘without liver fibrosis’ (median survival of 33 vs. 63 months, respectively). The worst prognosis of patients with subclinical liver fibrosis opens an intriguing scenario, in the context of a disease, like IPF, universally considered as being limited to the lungs. These preliminary data may indicate the usefulness of a systemic approach to clarify the possible correlation between the fibrotic process across lung and liver. More focused studies are needed to identify cellular/molecular pathways of response to injury—if any—that are shared by liver and lung fibrosis. Detection of a subgroup of patients with idiopathic fibrotic disease involving more organs would allow the definition of a new clinical phenotype, paving the way for future research. Future studies may also analyze whether short telomeres may contribute to such phenotype.

If common pathogenetic mechanisms between lung and liver fibrosis are identified, this would inevitably impact on the prognosis and treatment of IPF. Indeed, concomitant liver fibrosis may potentially influence response of IPF patients to antifibrotic drugs and may explain, at least in part, the variable degrees of functional decline and disease progression observed in both clinical trials and real-word studies of pirfenidone and nintedanib. Moreover, concomitant liver fibrosis may increase patient susceptibility to liver toxicity, which is one of the most common side effects of antifibrotic therapy.

In our population, we finally analyzed which indicators could be independent predictors of survival. Our data revealed that only lower levels of APRI are an independent predictor of survival in IPF patients (HR: 4.52; 95% CI 1.30–15.6; p = 0.02), which is added to the predictive role of liver fibrosis.

Our data are in line with the concept of a prognostic role played by comorbidities in IPF patients [32]. We can speculate that IPF is a multisystemic disease where risk stratification by comorbidities may impact on clinical practice and the design of new clinical trials.

The findings of our study should be seen in light of some limitations. First, our study did not include an age-matched control group. Second, the study population is relatively small; in particular, this might have prevented us to identify independent predictors of liver fibrosis in our population (no variables significantly associated with liver fibrosis at univariate analysis). However, it should be highlighted that IPF is a rare disease, and collecting a large number of patients is challenging. Third, patients with BMI> 29 (n = 6) were excluded due to the intrinsic limitation of the HTE technique while five patients were excluded based on their morphotype. As a result, our findings need to be further confirmed before being generalizable to the broader population of IPF patients.

In conclusion, our study shows that a relevant proportion of patients with IPF have also liver fibrosis; whether the co-existence of the two conditions is caused by common fibrogenic pathways needs to be explored further. In particular, this subset of IPF patients should be investigated for the carriage of telomerase mutations and telomere length. IPF has long been considered the prototypic disease limited to
the lung. However, if confirmed by larger studies, our data suggest that, at least in a subset of patients, IPF may be a part of multiorgan fibrotic phenotype.

Acknowledgements We want to thank Professional Editor Colin Woodham for language editing.

Author contributions EC and RT made substantial contribution to the concept, design, conduction of the study, and to the realization of the manuscript; thus, they both are ought to be considered as first authors. EC, RT, SC, and LR designed the study, enrolled patients, and wrote the paper. GA, IC, FP, and EB made substantial contributions to literature review, data collection, and paper writing. AV, FPR, FL, and AM reviewed the literature, wrote the manuscript, and produced the figures. AP critically reviewed and edited the manuscript. PS, LR, and EC designed the study, and reviewed and edited the manuscript. All the authors made substantial contribution to the realization of the work and approved the final version of the manuscript.

Funding None.

Data availability Data are available at the Respiratory Disease Unit of the University Hospital of Modena, Italy.

Compliance with ethical standards

Conflict of interest The authors have no competing interests with any organization or entity with a financial interest in competition with the subject, matter, or materials discussed in the manuscript.

Ethics approval and consent to participate Approval from the local ethics committee of Modena was obtained (Registered protocol no. 2645). Written informed consent to participate was obtained from all patients enrolled or their relatives, when appropriate.

Consent for publication Consent for publication was obtained from all patients enrolled.

References

1. Sgalla G, Cocconcelli E, Tonelli R, Richeldi L (2016) Novel drug targets for idiopathic pulmonary fibrosis. Expert Rev Respir Med 10(4):393–405. https://doi.org/10.1586/17476348.2016.1152186 Epub 2016 Feb 26
2. Wenzke KE, Cantemir-Stone C, Zhang J, Marsh CB, Huang, K. Identifying common genes and networks in multi-organ fibrosis. AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science, 2012, pp 106–115
3. Jun JJ, Lau LF (2018) Resolution of organ fibrosis. J Clin Invest 128(1):97–107
4. Zeisberg M, Kalluri R (2013) Cellular mechanisms of tissue fibrosis. I. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol Cell Physiol. 304(3):C216–C225. https://doi.org/10.1152/ajpcell.00328.2012
5. Selman M, King J, Pardo A (2001) Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134(2):136–151
6. Lederer DJ, Martinez FJ (2018) Idiopathic pulmonary fibrosis. NEJM 29(5):283–291
7. Raghu G, Collard HR, Egan JJ et al (2011) An Official ATS/ERS/JRS/ALAT Statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824
8. Raghu G, Remy-Jardin M, Myers JL et al (2018) American Thoracic Society diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 198(5):e44–e68
9. Ley B, Ryerson CJ, Vittinghoff E et al (2012) A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156(10):684–691
10. Galeni N, Humbert M, Vachery J-L et al (2015) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 46:903–975
11. Castera L, Forns X, Alberti A (2008) Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48(5):835–847
12. Platon ML, Stefanescu H, Feier D, Maniu A, Badea R (2013) Performance of unidimensional transient elastography in staging chronic hepatitis C. Results from a cohort of 1,202 biopsied patients from one single center. J Gastrointest Liver Dis 22(2):157–166
13. Lieber CS, Weiss DG, Morgan TR, Paronetto F (2006) Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol 101(7):1500–1508
14. Lin ZH, Xin YN, Dong QJ et al (2011) Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 53(3):726–736
15. Wynn TA, Ramalingam TR (2013) Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18(7):1028–1040
16. Friedman SL (2003) Liver fibrosis: from bench to bedside. J Hepatol 38(Suppl 1):S38–53
17. Schuppan D, Ruehl M, Somasundaram R, Hahn EG (2001) Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 21(3):351–372
18. Schölmerich J, Holstege A (1990) Aetiology and pathophysiology of chronic liver disorders. Drugs 40(3):3–22
19. Peregelyuk M, Terajima M, Wang AY et al (2013) Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagens and lysyl oxidases in normal liver and early after injury. Am J Physiol Gastrointest Liver Physiol 304(6):605–615
20. Armanios MY, Chen JLL, Cogdon JD et al (2007) Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 358(13):1317–1326
21. Armanios M (2009) Syndromes of telomere shortening. Annu Rev Genomics Hum Genet 10(1):45–61
22. Alder JK, Cogan JD, Brown AF et al (2011) Ancestral mutation in telomerase causes defects in repeat addition processivity and manifests as familial pulmonary fibrosis. PLoS Genet 7(3):1–9
23. Díaz de Leon A, Cronkhite JT, Katzenstein ALA et al (2010) Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One 5(5):e10680
24. Sandrin L, Fourquet B, Hasquenoph J-M et al (2003) Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29(12):1705–1713
25. Colletta C, Smirne C, Fabris C et al (2013) Telomere and TERT associations with success rate and performance of FibroScan measure- ments for the diagnosis of cirrhosis in HCV carriers with normal aminotransferases. Hepatology 42(4):838–845
26. Foucher J, Chanteloup E, Vergniol J et al (2006) Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55(3):403–408
27. Kettaneh A, Marcellin P, Douvin C et al (2007) Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol 46(4):628–634
28. Shaheen AAM, Wan AF, Myers RP (2007) FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a
systematic review of diagnostic test accuracy. Am J Gastroenterol 102(11):2589–2600
29. Wai C-T, Greenson JK, Fontana RJ et al (2003) A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38(2):518–526
30. Castéra L, Vergniol J, Foucher J et al (2005) Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128(2):343–350
31. Roulot D, Czernichow S, Le Clésiau H, Costes JL, Vergnaud AC, Beaugrand M (2008) Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 48(4):606–613
32. Torrisi SE, Ley B, Kreuter M et al (2019) The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study. Eur Respir J. 53(3):1801587 Published 2019 Mar 7

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Affiliations

Elisabetta Cocconcelli1 · Roberto Tonelli2,3 · Gianluca Abbat4 · Alessandro Marchioni2 · Ivana Castaniere2,3 · Filippo Pelizzaro5 · Francesco Paolo Russo5 · Alberto Vegetti4 · Elisabetta Balestro1 · Antonello Pietrangelo4 · Luca Richeldi6 · Fabrizio Luppi7 · Paolo Spagnolo1 · Enrico Clini2 · Stefania Cerri2

Elisabetta Cocconcelli
ecocconcelli@icloud.com
Roberto Tonelli
roberto.tonelli@me.com
Gianluca Abbat
abati.gianluca@policlinico.mo.it
Alessandro Marchioni
marchioni.alessandro@unimore.it
Ivana Castaniere
ivana.castaniere@unimore.it
Filippo Pelizzaro
filippo.pelizzaro@gmail.com
Francesco Paolo Russo
francescopaolo.russo@unipd.it
Alberto Vegetti
vegetti.alberto@policlinico.mo.it
Elisabetta Balestro
elisabetta.balestro@hotmail.com
Antonello Pietrangelo
antonello.pietrangelo@unimore.it
Luca Richeldi
luca.richeldi@unicatt.it
Fabrizio Luppi
fabrizio.luppi@unimore.it
Paolo Spagnolo
paolo.spagnolo@unipd.it
Stefania Cerri
stefania.cerri@unimore.it

1 Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University Hospital of Padova, Padua, Italy
2 Department of Medical and Surgical Sciences, University Hospital of Modena, Respiratory Diseases Unit and Centre for Rare Lung Diseases, University of Modena Reggio Emilia, Modena, Italy
3 Clinical and Experimental Medicine PhD Program, University of Modena Reggio Emilia, Modena, Italy
4 Department of Medical and Surgical Sciences, University Hospital of Modena, Internal Medicine Unit, University of Modena Reggio Emilia, Modena, Italy
5 Department of Surgical, Oncological and Gastroenterological Sciences, Unit of Gastroenterology, University of Padova, Padua, Italy
6 University Cattolica del Sacro Cuore, Respiratory Diseases Unit, University Hospital Agostino Gemelli, Rome, Italy
7 Respiratory Unit, S. Gerardo Hospital, University of Milano Bicocca, Monza, Italy